Literature DB >> 20371029

Rationale for, barriers to, and appropriate medication for the long-term treatment of depression.

David J Nutt1.   

Abstract

Antidepressants have proven efficacy in the treatment of acute depressive episodes and the prevention of relapse over the long-term. However, whether due to ignorance about the chronicity of depression, intolerable adverse effects, or an inappropriate fear of dependence, antidepressants are often discontinued after remission or recovery from an acute episode, which frequently leads to relapse or recurrence. This, in turn, increases the risk of subsequent poor treatment response and lifelong depressive chronicity. Clinicians should focus on preventing depressive relapse with long-term antidepressant pharmacotherapy, thereby improving patients' overall outcomes, particularly with patients at high risk for relapse. When patients with depression have comorbid anxiety, benzodiazepines may be useful but should be used only as short-term augmentation during the beginning phase of antidepressant treatment; long-term treatment of comorbid anxiety is better managed by antidepressants that also treat anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371029     DOI: 10.4088/JCP.9058se1c.02gry

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Therapeutic Effects of Extinction Learning as a Model of Exposure Therapy in Rats.

Authors:  Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Neuropsychopharmacology       Date:  2016-07-15       Impact factor: 7.853

2.  Depressive symptoms and reduced preventive care use in older adults: the mediating role of perceived access.

Authors:  Joshua M Thorpe; Carolyn T Thorpe; Korey A Kennelty; Betty A Chewning
Journal:  Med Care       Date:  2012-04       Impact factor: 2.983

3.  Adjunct treatment with ketamine enhances the therapeutic effects of extinction learning after chronic unpredictable stress.

Authors:  Denisse Paredes; Anna R Knippenberg; Sarah E Bulin; Lydia J Keppler; David A Morilak
Journal:  Neurobiol Stress       Date:  2022-07-08

4.  Hippocampal volume and total cell numbers in major depressive disorder.

Authors:  Justin A Cobb; Joy Simpson; Gouri J Mahajan; James C Overholser; George J Jurjus; Lesa Dieter; Nicole Herbst; Warren May; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Psychiatr Res       Date:  2012-11-30       Impact factor: 4.791

5.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

6.  The Impact of Treatments for Depression on the Dynamic Network Structure of Mental States: Two Randomized Controlled Trials.

Authors:  Evelien Snippe; Wolfgang Viechtbauer; Nicole Geschwind; Annelie Klippel; Peter de Jonge; Marieke Wichers
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

7.  Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis.

Authors:  Masaki Kato; Hikaru Hori; Takeshi Inoue; Junichi Iga; Masaaki Iwata; Takahiko Inagaki; Kiyomi Shinohara; Hissei Imai; Atsunobu Murata; Kazuo Mishima; Aran Tajika
Journal:  Mol Psychiatry       Date:  2020-07-23       Impact factor: 15.992

8.  Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission.

Authors:  Yumi Aoki; Yoshikazu Takaesu; Hajime Baba; Jun-Ichi Iga; Hikaru Hori; Takeshi Inoue; Kazuo Mishima; Aran Tajika; Masaki Kato
Journal:  Neuropsychopharmacol Rep       Date:  2022-07-01

9.  Multi-modality: a new approach for the treatment of major depressive disorder.

Authors:  Elliott Richelson
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-30       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.